Obiltoxaximab receives marketing authorization from European Commission for the treatment of Inhalation Anthrax

Media Center PRESS RELEASE 2020 OBILTOXAXIMAB RECEIVES MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR THE TREATMENT OF INHALATION ANTHRAX PARSIPPANY, NJ, DECEMBER 2, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that the European Commission has approved obiltoxaximab, the company’s monoclonal antibody (mAb) anthrax antitoxin for the treatment of inhalation anthrax. Obiltoxaximab is indicated in all age groups […]

Obiltoxaximab receives positive CHMP opinion for the treatment of Inhalation Anthrax

Media Center PRESS RELEASE 2020 OBILTOXAXIMAB RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF INHALATION ANTHRAX European Commission Decision Anticipated in November 2020 PARSIPPANY, NJ, OCTOBER 8, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing […]

Elusys Therapeutics receives Health Canada approval for Anthim® for the treatment for Inhalation Anthrax

Media Center PRESS RELEASE 2020 ELUSYS THERAPEUTICS RECEIVES HEALTH CANADA APPROVAL FOR ANTHIM® FOR THE TREATMENT OF INHALATION ANTHRAX PARSIPPANY, NJ, AUGUST 12, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for Anthim (obiltoxaximab for injection), the company’s monoclonal antibody (mAb) anthrax antitoxin for the treatment of […]